A cream for mild to moderate acne
Part of Skin clinical trials.
This study tests a cream containing ubiquinol, pomegranate peel extract, ceramide, and salicylic acid on people with mild-to-moderate acne. The goal is to see how it improves skin condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 40 years old.
- Your acne should be mild or moderate (not severe).
- You should not have other skin conditions like rosacea, eczema, or psoriasis.
- You cannot be pregnant or breastfeeding.
- You must not be allergic to any ingredients in the study cream.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a special cream made from a friendly bacteria (Lactobacillus) that is coated to help it stick to the skin. It is for people with mild to moderate acne who have not taken other acne treatments recently.
This study tests a cosmetic product alongside a standard prescription acne treatment for 12 weeks, then a maintenance phase to see if the product helps improve acne and skin appearance.
This trial tests skincare products designed for people with sensitive skin who have mild to moderate acne. The goal is to see if they safely and effectively reduce acne without irritating sensitive skin.
This study tests whether taking a probiotic supplement can improve acne by balancing the gut microbiome. You will be asked to take the supplement and attend follow-up visits to track changes in your skin.
This trial tests an mRNA vaccine designed to treat mild facial acne. It aims to see if the vaccine is safe and effective at reducing acne lesions.
This trial tests a cream called KR230109 for mild to moderate facial acne. The goal is to see if the cream is safe and helps reduce pimples and blackheads/whiteheads. You will be asked to use the cream as directed and attend study visits.
Hear when a new Acne trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.